Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33798415.
- Also identified by DOI 10.1016/j.stem.2021.03.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Accumulation of undifferentiated myeloid progenitors is a hallmark of AML, and targeting differentiation blockade represents a promising therapeutic strategy for AML. In this issue of Cell Stem Cell, Wang et al. (2021) conducted surface antigen-guided CRISPR screening and identified ZFP36L2 as a myeloid leukemia differentiation regulator and new therapeutic target.
Medical subject headings
- Clustered Regularly Interspaced Short Palindromic Repeats
- Leukemia, Myeloid, Acute